- Trials with a EudraCT protocol (14,198)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14,198 result(s) found for: Blood Test.
Displaying page 150 of 710.
EudraCT Number: 2004-004863-32 | Sponsor Protocol Number: BCBE/04/NEB-PAO/087 | Start Date*: 2006-03-08 |
Sponsor Name:Berlin-Chemie Menarini | ||
Full Title: EFFECTS OF NEBIVOLOL ON THE WALKING ABILITY IN PATIENTS WITH ESSENTIAL HYPERTENSION AND PERIPHERAL ARTERIAL DISEASE INTERMITTENT CLAUDICATION | ||
Medical condition: ESSENTIAL HYPERTENSION AND PERIPHERAL ARTERIAL DISEASE INTERMITTENT CLAUDICATION | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003356-21 | Sponsor Protocol Number: 00/0648-DXM2 | Start Date*: 2013-10-21 | |||||||||||
Sponsor Name:Profil Institut für Stoffwechselforschung GmbH | |||||||||||||
Full Title: A phase IIa, dose-finding, double-blind, placebo-controlled, double-dummy, randomized, eightfold cross-over study to investigate the glucose lowering effects of dextromethorphan alone or in combi... | |||||||||||||
Medical condition: Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002758-31 | Sponsor Protocol Number: ECD01 | Start Date*: 2006-12-22 | |||||||||||
Sponsor Name:EPOPLUS GmbH & Co.KG | |||||||||||||
Full Title: A randomized, double-blind, multi-centre, placebo-controlled, parallel-group study to examine the efficacy and safety of low dose Epoetin beta on wound healing in diabetes patients with foot ulcer | |||||||||||||
Medical condition: wound healing in diabetes patients with foot ulcer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005711-17 | Sponsor Protocol Number: AGT4HB | Start Date*: 2009-09-25 | ||||||||||||||||
Sponsor Name:St. Jude Children’s Research Hospital | ||||||||||||||||||
Full Title: AN OPEN LABEL DOSE-ESCALATION STUDY OF A SELF COMPLEMENTARY ADENO-ASSOCIATED VIRAL VECTOR (scAAV2/8-LP1-hFIXco) FOR GENE TRANSFER IN SUBJECTS WITH HEMOPHILIA B | ||||||||||||||||||
Medical condition: Gene therapy for Haemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male | |||||||||||||||||
Trial protocol: GB (Temporarily Halted) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003846-41 | Sponsor Protocol Number: AFX01-10 | Start Date*: 2008-03-20 | |||||||||||
Sponsor Name:Affymax, Inc. | |||||||||||||
Full Title: An Open-label, Multi-center, Extension Study to Evaluate the Safety and Tolerability of AF37702 Injection (Hematide™) for the Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidn... | |||||||||||||
Medical condition: Long-Term Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001938-41 | Sponsor Protocol Number: H8O-SB-GWBN(a) | Start Date*: 2007-02-07 | |||||||||||
Sponsor Name:Lilly Deutschland GmbH | |||||||||||||
Full Title: Effect of Exenatide plus Metformin vs. Premixed Human Insulin Aspart plus Metformin on Glycemic Control and Hypoglycemia in Patients with Inadequate Control of Type 2 Diabetes on Oral Antidiabetic ... | |||||||||||||
Medical condition: Type 2 Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017882-42 | Sponsor Protocol Number: RP103-03 | Start Date*: 2010-08-12 | |||||||||||
Sponsor Name:Raptor Therapeutics Inc. | |||||||||||||
Full Title: A Randomized, Crossover, Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients ... | |||||||||||||
Medical condition: Cystinosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005830-63 | Sponsor Protocol Number: 0485-CL-0004 | Start Date*: 2009-10-30 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis | |||||||||||||
Medical condition: Moderate to severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001219-22 | Sponsor Protocol Number: PGL11-021 | Start Date*: 2012-06-11 | ||||||||||||||||
Sponsor Name:PregLem S.A. | ||||||||||||||||||
Full Title: A Phase IIa study investigating the efficacy and safety of the c-Jun-N-Terminal Kinase (JNK) inhibitor PGL5001 versus placebo administered for up to 5 months with concomitant administration of depo... | ||||||||||||||||||
Medical condition: Peritoneal and/or ovarian endometriosis with an inflammatory component. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004342-28 | Sponsor Protocol Number: PKFT218-1602 | Start Date*: 2017-10-30 | |||||||||||
Sponsor Name:Flamel Ireland Ltd trading under the business name Avadel Ireland | |||||||||||||
Full Title: A comparative, open label, randomized, 2 periods, 2 sequence crossover study to assess the relative bioavailability of sodium oxybate for extended release oral suspension (FT218) formulation (singl... | |||||||||||||
Medical condition: A trial on healthy volunteer fore the development of a treatment for cataplexy and excessive daytime sleepiness in narcolepsy. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000664-85 | Sponsor Protocol Number: 8VWF03 | Start Date*: 2006-12-19 |
Sponsor Name:Bio Products Laboratory | ||
Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di... | ||
Medical condition: von Willebrand disease | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) PL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000709-10 | Sponsor Protocol Number: UKM12_0026 | Start Date*: 2014-12-19 | |||||||||||
Sponsor Name:Universitätsklinikum Münster | |||||||||||||
Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential | |||||||||||||
Medical condition: relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021718-41 | Sponsor Protocol Number: 214868-004-03 | Start Date*: 2011-03-03 | |||||||||||
Sponsor Name:Allergan Ltd | |||||||||||||
Full Title: A Pilot, Multicenter, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety and Efficacy of AGN-214868 in Patients with Idiopathic Overactive Bladder and Urinary Incontinence | |||||||||||||
Medical condition: To evaluate the safety and efficacy of AGN-214868 compared with placebo in the treatment of patients with idiopathic overactive bladder (IOAB) and urinary incontinence. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001598-18 | Sponsor Protocol Number: F1J‐MC‐HMCL | Start Date*: 2017-05-09 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001765-42 | Sponsor Protocol Number: REVERSE | Start Date*: 2007-02-01 |
Sponsor Name:UZ Brussel | ||
Full Title: A prospective and randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation (REVERSE st... | ||
Medical condition: New onset diabetes mellitus after renal transplantation. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002171-19 | Sponsor Protocol Number: HEVACC | Start Date*: 2021-05-12 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck, Institut für Virologie | |||||||||||||
Full Title: Heterologous vaccination with a Vaxzervia (ChAdOx1-S) prime and a Comirnaty (BNT162b2) boost | |||||||||||||
Medical condition: Immunization for SARS-CoV-2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003280-38 | Sponsor Protocol Number: PSY-NIL-0006 | Start Date*: 2016-05-04 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Positron Emission Tomography assessment of Ketamine Binding of the Serotonin Transporter and its Relevance for Rapid Antidepressant Response | |||||||||||||
Medical condition: 20 patients with severe unipolar depression (structured clinical interview for DSM-IV and the 17-item Hamilton Depression Rating Scale), also 20 age and sex matched healthy controls. plus 12 HC f... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003835-31 | Sponsor Protocol Number: IB2018-04 | Start Date*: 2021-09-28 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study | |||||||||||||
Medical condition: Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002069-22 | Sponsor Protocol Number: ET17-057 | Start Date*: 2018-04-18 | |||||||||||
Sponsor Name:CENTRE LEON BERARD | |||||||||||||
Full Title: BREASTIMMUNE02 - A multicenter, randomized, open-label, Phase II trial aiming to evaluate the impact of pegfilgrastim on trastuzumab anti-tumor effect and antibody-dependent cell-mediated cytotoxic... | |||||||||||||
Medical condition: Operable HER2 positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001416-30 | Sponsor Protocol Number: IDH2-Post-Allo-Trial | Start Date*: 2020-06-18 | |||||||||||
Sponsor Name:Heinrich-Heine-University Düsseldorf represented by the Coordinating Investigator | |||||||||||||
Full Title: IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS following allogeneic blood stem cell transplantation | |||||||||||||
Medical condition: Patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or acute myelogenous leukemia (AML) after allogeneic stem cell transplantation (allo-SCT) and with an IDH2 mutat... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
